Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease
Identifieur interne : 000E80 ( Main/Exploration ); précédent : 000E79; suivant : 000E81Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease
Auteurs : C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Anthony H. Schapira [Royaume-Uni] ; Murat Emre [Turquie] ; Helena Nissinen [Finlande] ; Mika Leinonen [Suède] ; Fabrizio Stocchi [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-07.
Abstract
The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) study compared the initiation of levodopa (l‐dopa) therapy with l‐dopa/carbidopa (LC) versus l‐dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE‐PD study population was investigated to determine the effect of l‐dopa dose and other risk factors on the development of dyskinesia and wearing‐off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing‐off were performed at 3‐month intervals for the 134‐ to 208‐week duration of the study. The patients were divided into 4 dose groups based on nominal l‐dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, <400 mg/day (n=157); group 2, 400 mg/day (n=310); group 3, 401 to 600 mg/day (n=201); and group 4, >600 mg/day (n=77). Similar analyses were performed with respect to wearing‐off and any motor complication. The times to onset and frequency of dyskinesia, wearing‐off, or any motor complication were compared using the log‐rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing‐off increased in an l‐dopa dose‐dependent manner (P<0.001 for both). Analyses using l‐dopa equivalent doses produced comparable results. Factors that were predictive of dyskinesia, in rank order, were: young age at onset, higher l‐dopa dose, low body weight, North American geographic region, LCE treatment group, female gender, and more severe Unified Parkinson's Disease Rating Scale (UPDRS) Part II. Multivariate analyses identified similar predictors for wearing‐off but included baseline UPDRS Part III and excluded weight and treatment allocation. The risk of developing dyskinesia or wearing‐off was closely linked to l‐dopa dose. The current results suggest that physicians should use the lowest dose of l‐dopa that provides satisfactory clinical control to minimize the risk of both dyskinesia and wearing‐off. © 2013 Movement Disorder Society
Url:
DOI: 10.1002/mds.25364
Affiliations:
- Autriche, Finlande, France, Italie, Royaume-Uni, Suède, Turquie, États-Unis
- Angleterre, Grand Londres, Latium, Midi-Pyrénées, Occitanie (région administrative), Svealand, Tyrol (Land), État de New York
- Innsbruck, Londres, Rome, Stockholm, Toulouse
- Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B17
- to stream Istex, to step Curation: 001B15
- to stream Istex, to step Checkpoint: 000087
- to stream Main, to step Merge: 000F08
- to stream Main, to step Curation: 000E80
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease</title><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Schapira, Anthony H" sort="Schapira, Anthony H" uniqKey="Schapira A" first="Anthony H." last="Schapira">Anthony H. Schapira</name></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></author><author><name sortKey="Nissinen, Helena" sort="Nissinen, Helena" uniqKey="Nissinen H" first="Helena" last="Nissinen">Helena Nissinen</name></author><author><name sortKey="Leinonen, Mika" sort="Leinonen, Mika" uniqKey="Leinonen M" first="Mika" last="Leinonen">Mika Leinonen</name></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D6F5876F824C5083C06BD5EC1A5EA71EB81002C1</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25364</idno><idno type="url">https://api.istex.fr/document/D6F5876F824C5083C06BD5EC1A5EA71EB81002C1/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B17</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001B17</idno><idno type="wicri:Area/Istex/Curation">001B15</idno><idno type="wicri:Area/Istex/Checkpoint">000087</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000087</idno><idno type="wicri:doubleKey">0885-3185:2013:Warren Olanow C:factors:predictive:of</idno><idno type="wicri:Area/Main/Merge">000F08</idno><idno type="wicri:Area/Main/Curation">000E80</idno><idno type="wicri:Area/Main/Exploration">000E80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease</title><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY</wicri:regionArea><wicri:noRegion>NY</wicri:noRegion></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Research, Scientific Institute for Care and Treatment, San Raffaele, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Clinical Investigation Center, Departments of Clinical Pharmacology and Neurosciences, and Faculty of Medicine, National Institute for Health and Medical Research Unit 455, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Schapira, Anthony H" sort="Schapira, Anthony H" uniqKey="Schapira A" first="Anthony H." last="Schapira">Anthony H. Schapira</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University Department of Clinical Neurosciences, Institute of Neurology, University College London, National Hospital for Neurology, and Neurosurgery and Royal Free Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name><affiliation wicri:level="1"><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Neurology, Istanbul University, Instanbul</wicri:regionArea><wicri:noRegion>Instanbul</wicri:noRegion></affiliation></author><author><name sortKey="Nissinen, Helena" sort="Nissinen, Helena" uniqKey="Nissinen H" first="Helena" last="Nissinen">Helena Nissinen</name><affiliation wicri:level="1"><country xml:lang="fr">Finlande</country><wicri:regionArea>Orion Pharma, Espoo</wicri:regionArea><wicri:noRegion>Espoo</wicri:noRegion></affiliation></author><author><name sortKey="Leinonen, Mika" sort="Leinonen, Mika" uniqKey="Leinonen M" first="Mika" last="Leinonen">Mika Leinonen</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>4Pharma AB, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute for Research, Scientific Institute for Care and Treatment, San Raffaele, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-07">2013-07</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1064">1064</biblScope><biblScope unit="page" to="1071">1071</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D6F5876F824C5083C06BD5EC1A5EA71EB81002C1</idno><idno type="DOI">10.1002/mds.25364</idno><idno type="ArticleID">MDS25364</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) study compared the initiation of levodopa (l‐dopa) therapy with l‐dopa/carbidopa (LC) versus l‐dopa/carbidopa/entacapone (LCE) in patients with Parkinson's disease. In the current study, the STRIDE‐PD study population was investigated to determine the effect of l‐dopa dose and other risk factors on the development of dyskinesia and wearing‐off. Patients were randomized to receive LCE (n=373) or LC (n=372). Blinded assessments for dyskinesia and wearing‐off were performed at 3‐month intervals for the 134‐ to 208‐week duration of the study. The patients were divided into 4 dose groups based on nominal l‐dopa dose at the time of onset of dyskinesia (or at study conclusion if there was no dyskinesia): group 1, <400 mg/day (n=157); group 2, 400 mg/day (n=310); group 3, 401 to 600 mg/day (n=201); and group 4, >600 mg/day (n=77). Similar analyses were performed with respect to wearing‐off and any motor complication. The times to onset and frequency of dyskinesia, wearing‐off, or any motor complication were compared using the log‐rank test (overall trend test) and a Cox proportional hazards model (pairwise comparisons). A stepwise Cox proportional hazards model was used to screen predictive factors in a multivariate analysis. The risk of developing dyskinesia and wearing‐off increased in an l‐dopa dose‐dependent manner (P<0.001 for both). Analyses using l‐dopa equivalent doses produced comparable results. Factors that were predictive of dyskinesia, in rank order, were: young age at onset, higher l‐dopa dose, low body weight, North American geographic region, LCE treatment group, female gender, and more severe Unified Parkinson's Disease Rating Scale (UPDRS) Part II. Multivariate analyses identified similar predictors for wearing‐off but included baseline UPDRS Part III and excluded weight and treatment allocation. The risk of developing dyskinesia or wearing‐off was closely linked to l‐dopa dose. The current results suggest that physicians should use the lowest dose of l‐dopa that provides satisfactory clinical control to minimize the risk of both dyskinesia and wearing‐off. © 2013 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Autriche</li><li>Finlande</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>Suède</li><li>Turquie</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Latium</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li><li>Svealand</li><li>Tyrol (Land)</li><li>État de New York</li></region><settlement><li>Innsbruck</li><li>Londres</li><li>Rome</li><li>Stockholm</li><li>Toulouse</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="États-Unis"><noRegion><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name></noRegion><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></country><country name="Italie"><region name="Latium"><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name></region><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></country><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Schapira, Anthony H" sort="Schapira, Anthony H" uniqKey="Schapira A" first="Anthony H." last="Schapira">Anthony H. Schapira</name></region></country><country name="Turquie"><noRegion><name sortKey="Emre, Murat" sort="Emre, Murat" uniqKey="Emre M" first="Murat" last="Emre">Murat Emre</name></noRegion></country><country name="Finlande"><noRegion><name sortKey="Nissinen, Helena" sort="Nissinen, Helena" uniqKey="Nissinen H" first="Helena" last="Nissinen">Helena Nissinen</name></noRegion></country><country name="Suède"><region name="Svealand"><name sortKey="Leinonen, Mika" sort="Leinonen, Mika" uniqKey="Leinonen M" first="Mika" last="Leinonen">Mika Leinonen</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D6F5876F824C5083C06BD5EC1A5EA71EB81002C1
|texte= Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |